Their active ingredient, semaglutide, regulates appetite and makes the body feel fuller faster, reducing food intake
"Obesity is a chronic condition and thus requires long-term treatment," says Shalev, who believes the field is moving toward a two-step approach: using a GLP-1 to achieve weight loss, followed by a different medication to help maintain it
If a GLP-1 medication helps you lose a significant amount of weight (often 10% or more of your body weight), your current dose of levothyroxine may become too high
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]